» Articles » PMID: 35054957

Nanocarriers for Delivery of Oligonucleotides to the CNS

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jan 21
PMID 35054957
Authors
Affiliations
Soon will be listed here.
Abstract

Nanoparticles with oligonucleotides bound to the outside or incorporated into the matrix can be used for gene editing or to modulate gene expression in the CNS. These nanocarriers are usually optimised for transfection of neurons or glia. They can also facilitate transcytosis across the brain endothelium to circumvent the blood-brain barrier. This review examines the different formulations of nanocarriers and their oligonucleotide cargoes, in relation to their ability to enter the brain and modulate gene expression or disease. The size of the nanocarrier is critical in determining the rate of clearance from the plasma as well as the intracellular routes of endothelial transcytosis. The surface charge is important in determining how it interacts with the endothelium and the target cell. The structure of the oligonucleotide affects its stability and rate of degradation, while the chemical formulation of the nanocarrier primarily controls the location and rate of cargo release. Due to the major anatomical differences between humans and animal models of disease, successful gene therapy with oligonucleotides in humans has required intrathecal injection. In animal models, some progress has been made with intraventricular or intravenous injection of oligonucleotides on nanocarriers. However, getting significant amounts of nanocarriers across the blood-brain barrier in humans will likely require targeting endothelial solute carriers or vesicular transport systems.

Citing Articles

Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges.

Bandara S, Raveendran S Cancers (Basel). 2025; 17(5).

PMID: 40075668 PMC: 11899461. DOI: 10.3390/cancers17050821.


Combined Albumin Polyester Nanocarriers with Docetaxel for Effective Against Lung Cancer in Mice Model.

Yang Y, Ye T, Shang F, Chen D, Wang K, He S Int J Nanomedicine. 2025; 20:2103-2118.

PMID: 39990292 PMC: 11844320. DOI: 10.2147/IJN.S487344.


Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives.

Luis M, Goes M, Santos F, Mesquita J, Tavares-Ratado P, Tomaz C Pharmaceutics. 2025; 17(1).

PMID: 39861752 PMC: 11768343. DOI: 10.3390/pharmaceutics17010104.


Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases.

Ozceylan O, Sezgin-Bayindir Z ACS Omega. 2024; 9(33):35223-35242.

PMID: 39184484 PMC: 11340000. DOI: 10.1021/acsomega.4c01774.


Alzheimer's Disease Treatment: The Search for a Breakthrough.

Reiss A, Muhieddine D, Jacob B, Mesbah M, Pinkhasov A, Gomolin I Medicina (Kaunas). 2023; 59(6).

PMID: 37374288 PMC: 10302500. DOI: 10.3390/medicina59061084.


References
1.
Amado D, Davidson B . Gene therapy for ALS: A review. Mol Ther. 2021; 29(12):3345-3358. PMC: 8636154. DOI: 10.1016/j.ymthe.2021.04.008. View

2.
Moore L, Rajpal G, Dillingham I, Qutob M, Blumenstein K, Gattis D . Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. Mol Ther Nucleic Acids. 2017; 7:200-210. PMC: 5415970. DOI: 10.1016/j.omtn.2017.04.005. View

3.
Yu Y, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y . Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011; 3(84):84ra44. DOI: 10.1126/scitranslmed.3002230. View

4.
Giorgio E, Lorenzati M, Rivetti di Val Cervo P, Brussino A, Cernigoj M, Della Sala E . Allele-specific silencing as treatment for gene duplication disorders: proof-of-principle in autosomal dominant leukodystrophy. Brain. 2019; 142(7):1905-1920. DOI: 10.1093/brain/awz139. View

5.
Etame A, Smith C, Chan W, Rutka J . Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine. 2011; 7(6):992-1000. DOI: 10.1016/j.nano.2011.04.004. View